Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
Top Cited Papers
Open Access
- 5 December 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 71 (3), 555-564
- https://doi.org/10.1007/s00280-012-2042-4
Abstract
Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors due to its well-defined mechanism of action, demonstrated anticancer activity and its ability to be combined with other agents. VCR is an M-phase cell cycle-specific anticancer drug with activity that is concentration and exposure duration dependent. The pharmacokinetic profile of standard VCR is described by a bi-exponential elimination pattern with a very fast initial distribution half-life followed by a longer elimination half-life. VCR also has a large volume of distribution, suggesting diffuse distribution and tissue binding. These properties may limit optimal drug exposure and delivery to target tissues as well as clinical utility as a single agent or as an effective component of multi-agent regimens. Vincristine sulfate liposome injection (VSLI), Marqibo®, is a sphingomyelin and cholesterol-based nanoparticle formulation of VCR that was designed to overcome the dosing and pharmacokinetic limitations of standard VCR. VSLI was developed to increase the circulation time, optimize delivery to target tissues and facilitate dose intensification without increasing toxicity. In xenograft studies in mice, VSLI had a higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug to target tissues compared to standard VCR. VSLI recently received accelerated FDA approval for use in adults with advanced, relapsed and refractory Philadelphia chromosome-negative ALL and is in development for untreated adult ALL, pediatric ALL and untreated aggressive NHL. Here, we summarize the nonclinical data for VSLI that support its continued clinical development and recent approval for use in adult ALL.Keywords
This publication has 55 references indexed in Scilit:
- Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007Blood, 2012
- Outcome of adults with acute lymphocytic leukemia after second salvage therapyCancer, 2008
- In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumorsInternational Journal of Cancer, 2004
- Liposomal Drug FormulationsDrugs, 1998
- Polymerization of Tubulin in Apoptotic Cells Is Not Cell Cycle DependentExperimental Cell Research, 1994
- Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogsAnti-Cancer Drugs, 1994
- Vinca alkaloids: Anti-vascular effects in a murine tumourEuropean Journal of Cancer, 1993
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI Journal of the National Cancer Institute, 1992
- Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanismEuropean Journal of Cancer and Clinical Oncology, 1991
- Relative mutagenicity of antineoplastic drugs and other alkylating agents in V79 chinese hamster cells, independence of cytotoxic and mutagenic responsesMutation research. Reviews in mutation research, 1980